

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 February 2001 (01.02.2001)

PCT

(10) International Publication Number
WO 01/07039 A2

(51) International Patent Classification⁷: **A61K 31/205**

(21) International Application Number: **PCT/IT00/00313**

(22) International Filing Date: **25 July 2000 (25.07.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
RM99A000483 28 July 1999 (28.07.1999) IT

(71) Applicant (for all designated States except US):
SIGMA-TAU HEALTHSCIENCE S.P.A. [IT/IT];
Via Treviso, 4, I-00040 Pomezia (IT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **CAVAZZA, Claudio**
[IT/IT]; Piazza Campitelli, 2, I-00186 Roma (IT).

(74) Agents: **CAVATTONI, Fabio et al.; Cavattoni - Raimondi,**
Viale dei Parioli, 160, I-00197 Roma (IT).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **COMPOSITION FOR THE PREVENTION AND TREATMENT OF KIDNEY DYSFUNCTIONS AND DISEASES**

(57) Abstract: A composition is disclosed which is suitable for the prevention and treatment of kidney dysfunctions and diseases and which can therefore take the form of a food supplement or of an actual medicinal drug, comprising a combination of aceryl L-carnitine and propionyl L-carnitine or their pharmacologically acceptable salts.

WO 01/07039 A2